CDC will work
with OMB regarding the disclosure board protocol and any other
protocols associated with the retrospective collection of lab
data.
Inventory as of this Action
Requested
Previously Approved
12/31/2020
6 Months From Approved
16,774
0
0
65,936
0
0
0
0
0
Ensuring a rapid and thorough public
health response to the COVID-19 pandemic necessitates comprehensive
laboratory testing data. These data contribute to understanding
disease incidence and trends: initiating epidemiology case
investigations, assisting with contact tracing, assessing
availability and use of testing resources, and identifying supply
chain issues for reagents and other material. Laboratory testing
data, in conjunction with case reports and other data, also provide
vital guidance for mitigation and control activities.
This information is
essential to ensuring a rapid and thorough public health response
to the COVID-19 pandemic. Comprehensive laboratory testing data
contribute to understanding disease incidence and trends:
initiating epidemiologic case investigations, assisting with
contact tracing, assessing availability and use of testing
resources, and identifying of supply chain issues for reagents and
other material. Laboratory testing data, in conjunction with case
reports and other data, also provide vital guidance for mitigation
and control activities. CDC cannot reasonably comply with the
normal clearance given the ongoing public health emergency.
Laboratory data serve not only as important information to support
decision making related to the public health emergency, but also as
a critical piece to better understanding the performance of tests
in real-world conditions, the effectiveness of clinical
interventions, and patient outcomes and interventions. Better
understanding the characteristics and performance of specific tests
can help ensure that healthcare providers are equipped with the
maximum information necessary to make clinical decisions, develop
recommendations and provide the most appropriate care for their
patients. Additionally, with widespread use of electronic health
records (EHR), closing the loop by incorporating information
related to laboratory testing can add to the robustness of data
that will eventually serve as the backbone for clinical research to
inform treatments, better understand outcomes, improve the quality
and performance of diagnostic tests over time, and shape clinical
understanding of COVID-19.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.